{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:51:23Z","timestamp":1792291883821,"version":"4.4.0"},"reference-count":113,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Claudin 18.2 (CLDN18.2) has rapidly become a major target in solid-tumor oncology. Zolbetuximab, the first anti-CLDN18.2 antibody, was approved in 2024 for HER2-negative, CLDN18.2-high advanced gastric and gastro-esophageal junction adenocarcinoma, and more than one hundred CLDN18.2-directed trials are now under way across monoclonal antibodies, antibody-drug conjugates, bispecific antibodies and CAR-T cells. As these agents enter the clinic, resistance has become the central challenge. This review synthesizes the resistance mechanisms emerging from this experience and organizes them into six biological dimensions, separating those distinctive to CLDN18.2 from those shared across therapeutic platforms, and pairs each with mechanism-matched countermeasures weighted by level of evidence. From this synthesis we advance a central argument about treatment sequencing: because CLDN18.2 expression declines progressively under therapeutic pressure, continuous target-plus-chemotherapy acts on an eroding antigen substrate. For patients with high, homogeneous baseline expression, an early intensive induction followed by CLDN18.2-directed maintenance may therefore be preferable to indefinite target-plus-chemotherapy. We further consider the tissue-context-dependent biology of CLDN18.2 relevant to patient selection, and outline the prospective, biomarker-embedded trials needed to test these proposals.<\/jats:p>","DOI":"10.3389\/fonc.2026.1910011","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:32:51Z","timestamp":1787743971000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Resistance mechanisms and countermeasures in CLDN18.2-positive tumors: from molecular networks to clinical practice"],"prefix":"10.3389","volume":"16","author":[{"given":"Yutao","family":"Xia","sequence":"first","affiliation":[{"name":"Department of Oncology, Weifang Yidu Central Hospital","place":["Weifang, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Weifang Yidu Central Hospital","place":["Weifang, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taosheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Weifang Yidu Central Hospital","place":["Weifang, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Oncology, Weifang Yidu Central Hospital","place":["Weifang, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Weifang Yidu Central Hospital","place":["Weifang, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.gene.2011.04.007","article-title":"Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals","volume":"481","author":"T\u00fcreci","year":"2011","journal-title":"Gene"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1523096","article-title":"Characterization of zolbetuximab in pancreatic cancer models","volume":"8","author":"T\u00fcreci","year":"2019","journal-title":"Oncoimmunology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz199","article-title":"A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study","volume":"30","author":"T\u00fcreci","year":"2019","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00874-2","article-title":"Claudin 18.2 as a novel therapeutic target","volume":"21","author":"Nakayama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0508-4","article-title":"Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases","volume":"121","author":"Coati","year":"2019","journal-title":"Br J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-025-04138-x","article-title":"Concordance of laboratory assays for claudin 18.2 in gastric cancer tissue samples: independent proficiency testing and a descriptive non-interventional study","volume":"487","author":"R\u00f6cken","year":"2025","journal-title":"Virchows Arch"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-2025-111","article-title":"Retrospective analysis of CLDN18.2 expression in ethnically diverse patients with gastroesophageal adenocarcinoma","volume":"16","author":"Wallam","year":"2025","journal-title":"J Gastrointest Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.14670\/HH-18-477","article-title":"Investigation of clinical application of claudin 18 isoform 2 in pancreatic ductal adenocarcinoma: a retrospective analysis of 302 Chinese patients","volume":"37","author":"Zhang","year":"2022","journal-title":"Histol Histopathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102362","article-title":"Claudin 18 (43-14A clone) expression in pancreatic ductal adenocarcinoma: assessment of a potential clinical biomarker for zolbetuximab therapy","volume":"55","author":"Arseneau","year":"2025","journal-title":"Transl Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100712","article-title":"Claudin 18.2 expression in 1404 digestive tract adenocarcinomas including 1175 colorectal carcinomas: distinct colorectal carcinoma subtypes are claudin 18.2 positive","volume":"38","author":"McHugh","year":"2025","journal-title":"Mod Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/his.15407","article-title":"Expression of claudin-18.2 in cholangiocarcinoma: a comprehensive immunohistochemical analysis from a German tertiary centre","volume":"86","author":"Kinzler","year":"2025","journal-title":"Histopathology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231217967","article-title":"Zolbetuximab for CLDN18.2-positive gastric or gastroesophageal junction cancer","volume":"16","author":"Kubota","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15245742","article-title":"Claudin18.2 in advanced gastric cancer","volume":"15","author":"Inamoto","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-025-01552-x","article-title":"Clinical pharmacology profile of the claudin 18.2 antibody zolbetuximab","volume":"64","author":"Yang","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.10.127","article-title":"Zolbetuximab plus mFOLFOX6\/CAPOX as first-line (1L) treatment in patients with claudin 18 isoform 2 positive (CLDN18.2+) metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma with peritoneal metastases: a post hoc analysis of SPOTLIGHT and GLOW [abstract","volume":"36","author":"Xu","year":"2025","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02056-x","article-title":"Zolbetuximab: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf185","article-title":"New tool in the toolbox: patient selection for zolbetuximab in advanced treatment-na\u00efve gastric\/gastroesophageal junction adenocarcinoma","volume":"30","author":"Grewal","year":"2025","journal-title":"Oncologist"},{"key":"B21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s00432-026-06447-3","article-title":"Diagnostic and therapeutic challenges in claudin 18.2-positive gastric cancer treated with zolbetuximab: intrapatient heterogeneity or secondary loss of expression","volume":"152","author":"Morath","year":"2026","journal-title":"J Cancer Res Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17233764","article-title":"CLDN18.2-targeted therapy in gastrointestinal cancers","volume":"17","author":"Dominguez Wiscovitch","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5230\/jgc.2024.24.e6","article-title":"Emerging targets for systemic treatment of gastric cancer: HER2 and beyond","volume":"24","author":"Kim","year":"2024","journal-title":"J Gastric Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"192","DOI":"10.5230\/jgc.2025.25.e3","article-title":"Spatial and temporal tumor heterogeneity in gastric cancer: discordance of predictive biomarkers","volume":"25","author":"Lee","year":"2025","journal-title":"J Gastric Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.5230\/jgc.2025.25.e2","article-title":"Discordance in claudin 18.2 expression between primary and metastatic lesions in patients with gastric cancer","volume":"25","author":"Son","year":"2025","journal-title":"J Gastric Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-025-03189-6","article-title":"Spatial discordance of claudin18.2 in gastric cancer: clinical implications for patient selection in zolbetuximab therapy","volume":"56","author":"Ozawa","year":"2026","journal-title":"Surg Today"},{"key":"B27","doi-asserted-by":"publisher","first-page":"17648","DOI":"10.1038\/s41598-024-68411-w","article-title":"Heterogeneity of claudin 18.2 expression in metastatic gastric cancer","volume":"14","author":"Choi","year":"2024","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012683","article-title":"Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapy","volume":"13","author":"Lim","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41416-025-02981-y","article-title":"Claudin18.2-positive gastric cancer-specific changes in neoadjuvant chemotherapy-driven immunosuppressive tumor microenvironment","volume":"132","author":"Tsutsumi","year":"2025","journal-title":"Br J Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03037-z","article-title":"CLDN18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01800-8","article-title":"CLDN18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03783-8","article-title":"CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial","volume":"31","author":"Liu","year":"2025","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115808","article-title":"Tecotabart vedotin in claudin 18.2-positive advanced gastric\/gastroesophageal junction cancer: a Bayesian phase 1\/2 clinical trial","volume":"230","author":"Bai","year":"2025","journal-title":"Eur J Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00636-3","article-title":"Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial","volume":"26","author":"Ruan","year":"2025","journal-title":"Lancet Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101710","article-title":"CMG901, a claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors","volume":"5","author":"Xu","year":"2024","journal-title":"Cell Rep Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14737140.2026.2615855","article-title":"Zolbetuximab as a gastric lineage-directed immunotherapy: mechanistic rationale and translational evidence in CLDN18.2-positive gastroesophageal adenocarcinoma","author":"Egebjerg","year":"2026","journal-title":"Expert Rev Anticancer Ther"},{"key":"B38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/14712598.2026.2617271","article-title":"Targeting claudin 18.2 in gastric cancer: a review of emerging biologic agents","volume":"26","author":"Yamamoto","year":"2026","journal-title":"Expert Opin Biol Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-025-01703-w","article-title":"Antibody-drug conjugates in gastric cancer: clinical advances and resistance mechanisms","volume":"29","author":"Li","year":"2026","journal-title":"Gastric Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/21688370.2021.1967080","article-title":"Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials","volume":"10","author":"Kyuno","year":"2022","journal-title":"Tissue Barriers"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-2025-637","article-title":"Claudin 18.2 in gastroesophageal adenocarcinoma: prevalence, biomarker associations, and implications for equity","volume":"16","author":"Alami Idrissi","year":"2025","journal-title":"J Gastrointest Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154068","article-title":"Expression and prognostic analysis of CLDN18 and claudin18.2 in lung adenocarcinoma","volume":"238","author":"Liu","year":"2022","journal-title":"Pathol Res Pract"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251361880","article-title":"Clinical and pathological analyses of gastric-type cervical adenocarcinoma and its prognostic relevance","volume":"17","author":"Xi","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221083049","article-title":"The dawn of precision medicine in diffuse-type gastric cancer","volume":"14","author":"Ooki","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154699","article-title":"Correlation of claudin18.2 expression with clinicopathological characteristics and prognosis in gastric cancer","volume":"248","author":"Tao","year":"2023","journal-title":"Pathol Res Pract"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03238-7","article-title":"Dichotomous roles of claudins as tumor promoters or suppressors: lessons from knockout mice","volume":"76","author":"Kage","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"10263","DOI":"10.1038\/s41598-026-39540-1","article-title":"Claudin18.2 promote gastric cancer proliferation by activating MCM2\/5","volume":"16","author":"Zheng","year":"2026","journal-title":"Sci Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.2024.J114","article-title":"The ZIC2-claudin-18.2 axis stimulates pancreatic cancer progression and metastasis via activation of the ERK1\/2 signaling pathway","volume":"266","author":"Zhou","year":"2025","journal-title":"Tohoku J Exp Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.24976\/Discov.Med.202537203.255","article-title":"Impact of aberrant CLDN18.2 expression on intercellular junction stability in gastric cancer cells","volume":"37","author":"Li","year":"2025","journal-title":"Discov Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.407","article-title":"CLARITY-Gastric 01: a randomised phase III study of AZD0901, a claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC\/GEJC) [abstract","volume":"35","author":"Shitara","year":"2024","journal-title":"Ann Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"S1843","DOI":"10.1016\/j.annonc.2025.10.096","article-title":"Updated results from a phase I study of JS107, a claudin 18.2 (CLDN18.2)-targeting antibody-drug conjugate (ADC), in combination with toripalimab and chemotherapy as the first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma (G\/GEJA) [abstract","volume":"36","author":"Xu","year":"2025","journal-title":"Ann Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1158\/1538-7445.AM2024-3140","article-title":"BL-M05D1, a novel claudin 18.2-targeting ADC, demonstrates specific potent anti-tumor efficacy in preclinical evaluation [abstract","volume":"84","author":"Wan","year":"2024","journal-title":"Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-025-04332-x","article-title":"Histological and biomarker landscape of Claudin18.2-positive gastric and gastroesophageal junction cancers: a study of 937 cases","author":"Zhang","year":"2025","journal-title":"Virchows Arch"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2025.100206","article-title":"Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancer","volume":"9","author":"Yamamoto","year":"2025","journal-title":"ESMO Gastrointest Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-026-02972-w","article-title":"Intratumoral heterogeneity and chemotherapy-induced alteration of CLDN18.2 expression in resectable gastric cancer","volume":"31","author":"Nagano","year":"2026","journal-title":"Int J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-334667","article-title":"Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy","volume":"75","author":"Sheng","year":"2026","journal-title":"Gut"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-335790","article-title":"Trogocytosis-orchestrated CLDN18.2-\"dressed\" CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade","author":"Zhou","year":"2026","journal-title":"Gut"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01214","article-title":"Coadministration of CD19- and CD22-directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II trial","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/membranes12080731","article-title":"Functional analysis of gastric tight junction proteins in Xenopus laevis oocytes","volume":"12","author":"Stein","year":"2022","journal-title":"Membranes (Basel)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03100-7","article-title":"Challenges and perspectives of CAR-T cell therapy in solid tumours: insights from gastric cancer","volume":"133","author":"Zhou","year":"2025","journal-title":"Br J Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"9650","DOI":"10.1038\/s41467-025-61858-z","article-title":"On-target off-tumor toxicity of claudin18.2-directed CAR-T cells in preclinical models","volume":"16","author":"Birocchi","year":"2025","journal-title":"Nat Commun"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01097-2","article-title":"Diffuse gastric cancer: a comprehensive review of molecular features and emerging therapeutics","volume":"19","author":"Wu","year":"2024","journal-title":"Target Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"408","DOI":"10.5230\/jgc.2020.20.e33","article-title":"Clinical significance of CLDN18.2 expression in metastatic diffuse-type gastric cancer","volume":"20","author":"Kim","year":"2020","journal-title":"J Gastric Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12916-022-02421-1","article-title":"Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer","volume":"20","author":"Jia","year":"2022","journal-title":"BMC Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12967-025-06276-x","article-title":"IDO1 inhibition enhances CLDN18.2-CAR-T cell therapy in gastrointestinal cancers by overcoming kynurenine-mediated metabolic suppression in the tumor microenvironment","volume":"23","author":"Wu","year":"2025","journal-title":"J Transl Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03015-3","article-title":"Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell treatment resistance in advanced gastric cancer","volume":"132","author":"Li","year":"2025","journal-title":"Br J Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2017.10.008","article-title":"Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM\/CD3-bispecific BiTE antibody MT110 efficacy against IDO1hi breast cancer via enhancing immune cells activity","volume":"54","author":"Hong","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.4244","article-title":"Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer","volume":"33","author":"Le","year":"2015","journal-title":"J Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nat Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0099","article-title":"Open-label, phase I study of nivolumab combined with nab-paclitaxel plus gemcitabine in advanced pancreatic cancer","volume":"26","author":"Wainberg","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41420-024-02167-0","article-title":"Enhancing antitumor efficacy of CLDN18.2-directed antibody-drug conjugates through autophagy inhibition in gastric cancer","volume":"10","author":"Xue","year":"2024","journal-title":"Cell Death Discov"},{"key":"B76","doi-asserted-by":"publisher","first-page":"315ra188","DOI":"10.1126\/scitranslmed.aac4925","article-title":"Trastuzumab emtansine (T-DM1) renders HER2-positive breast cancer highly susceptible to CTLA-4\/PD-1 blockade","volume":"7","author":"M\u00fcller","year":"2015","journal-title":"Sci Transl Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011857","article-title":"An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release","volume":"13","author":"Gaspar","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006704","article-title":"CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation","volume":"11","author":"Gao","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid Malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with Malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1494131","article-title":"Pan-cancer analysis of CLDN18.2 shed new insights on the targeted therapy of upper gastrointestinal tract cancers","volume":"15","author":"Wu","year":"2024","journal-title":"Front Pharmacol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06234-z","article-title":"First-in-human CLDN18.2 functional diagnostic PET imaging of digestive system neoplasms enables whole-body target mapping and lesion detection","volume":"50","author":"Wang","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267110","article-title":"68Ga-NC-BCH whole-body PET imaging rapidly targets Claudin18.2 in lesions in gastrointestinal cancer patients","volume":"65","author":"Qi","year":"2024","journal-title":"J Nucl Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-024-11186-5","article-title":"Relationship between [18F]FDG PET\/CT findings and claudin 18.2 expression in metastatic gastric cancer","volume":"35","author":"Yin","year":"2024","journal-title":"Eur Radiol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-026-07877-4","article-title":"Imaging-based stratification of Claudin 18.2-positive gastric adenocarcinoma using 18F-FDG PET\/CT radiomics","volume":"53","author":"Sun","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2026.108021","article-title":"Artificial intelligence-based prediction of claudin 18.2 expression and immune phenotype from routine histology to guide treatment decisions in patients with gastric cancer","volume":"11","author":"Kim","year":"2026","journal-title":"ESMO Open"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.09.010","article-title":"CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-\u03baB\/SDF-1\u03b1 axis to enhance efficacy against pancreatic cancer","volume":"31","author":"Sun","year":"2023","journal-title":"Mol Ther"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-04597-8","article-title":"Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2\u00d7CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study","volume":"24","author":"Li","year":"2026","journal-title":"BMC Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1484","article-title":"Impact of HER2 and PD-L1 co-expression in Claudin18.2 positive resectable gastroesophageal cancers [abstract","volume":"34","author":"Cammarota","year":"2023","journal-title":"Ann Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32110648","article-title":"Zolbetuximab or immunotherapy as the initial targeted therapy in CLDN18.2-positive, HER2-negative advanced gastric cancer: weighing the options","volume":"32","author":"Easaw","year":"2025","journal-title":"Curr Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-024-01417-3","article-title":"A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function","volume":"42","author":"Yue","year":"2024","journal-title":"Invest New Drugs"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01505-6","article-title":"Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination","volume":"27","author":"Ogawa","year":"2024","journal-title":"Gastric Cancer"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-026-00913-3","article-title":"Claudin proteins as emerging therapeutic targets for solid tumours","volume":"26","author":"Saviano","year":"2026","journal-title":"Nat Rev Cancer"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-336277","article-title":"KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy","volume":"75","author":"Liu","year":"2026","journal-title":"Gut"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.17802","article-title":"High Claudin 18.2 expression predicts favorable outcomes in pancreatic ductal adenocarcinoma after curative resection","volume":"45","author":"Cha","year":"2025","journal-title":"Anticancer Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13919","article-title":"Clinical implications of Claudin18.2 expression in patients with gastric cancer","volume":"39","author":"Baek","year":"2019","journal-title":"Anticancer Res"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216479","article-title":"Claudin-1 interacts with EPHA2 to promote cancer stemness and chemoresistance in colorectal cancer","volume":"579","author":"Primeaux","year":"2023","journal-title":"Cancer Lett"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41392-026-02621-8","article-title":"Efficacy and immunomodulatory effect of CLDN18.2-specific IL-7\/XCL1 armored CAR-T cells in digestive tract cancer: preclinical and clinical analysis","volume":"11","author":"Zhao","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1080\/20468954.2025.2535943","article-title":"Trispecific anti-CLDN-18.2\/CD3\/CD28 antibodies for gastric cancer treatment","volume":"13","author":"Flores-Robles","year":"2024","journal-title":"Pharm Pat Anal"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1007\/s12275-024-00133-0","article-title":"Genetically engineered CLDN18.2 CAR-T cells expressing synthetic PD1\/CD28 fusion receptors produced using a lentiviral vector","volume":"62","author":"Lee","year":"2024","journal-title":"J Microbiol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1910011\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:32:52Z","timestamp":1787743972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1910011\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":113,"alternative-id":["10.3389\/fonc.2026.1910011"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1910011","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1910011"}}